influenza. 1 Vaccination against influenza infection decreases heart-related hospital admissions, acute CHF exacerbations, and all-cause mortality. 2 Despite widespread influenza vaccination programs, overall influenza-related hospitalizations and mortality rates are rising, particularly in patients with cardiac disease. 1 Older adults and persons with cardiac disease or other comorbidities and treatments that render them immunocompromised are at elevated risk for influenza infection despite vaccination because of their reduced antibody and cellmediated vaccine responses. 3, 4 In patients with CHF, an upregulated sympathetic nervous system 5 may activate ␤ 2 -adrenergic receptors, reducing the cytokine production necessary for vaccine immune response. 6, 7 Therefore, it is logical that patients with CHF have higher influenza-related morbidity and mortality rates compared with individuals without cardiac disease, potentially due to upregulation of adrenergic pathways.
Most adults develop both humoral antibody and T-cell immune responses after influenza vaccination, indicating that both type 1 (T helper 1) and type 2 (T helper 2) responses occur after influenza immunization. [8] [9] [10] The most widely accepted indicators of an immune response to influenza vaccine are seroconversion and seroprotection, which refer to changes in antibody titers in reaction to one of the three viral strains used in the vaccine. However, postvaccination antibody titers as a measure of vaccine effectiveness in protecting against influenza illness in older adults do not measure cell-mediated immunity, which is particularly affected by disease and increasing age. 11 Previous research, including our own work, into the immune responses of CHF was based on in vitro methods to measure T-cell-mediated response that can be highly variable. 12, 13 In this study, we measured T-cell responses to influenza vaccination using trans vivo delayedtype hypersensitivity, a novel method to investigate T-cell function and sensitization under physiologic conditions. We hypothesized that patients with CHF mount less vigorous Tcell responses to influenza vaccination compared with those of healthy individuals.
Methods

Study Design and Participants
This prospective, open-label study compared differences in T-cell-mediated immune responses to influenza vaccination between healthy subjects (controls) and individuals who had established CHF, were receiving stable medical therapy, and were participating in the Advanced Heart Disease Program at the University of Wisconsin Hospital (Madison, WI). To be included in the study, patients with CHF had to have systolic or diastolic dysfunction, documented by echocardiography in the previous 6 months, and their CHF had to be classified as American College of CardiologyAmerican Heart Association stage C and New York Heart Association (NYHA) functional class I, II, or III. They had to have received stable medical therapy for CHF in the previous 30 days, including target or maximally tolerated doses of angiotensin-converting enzyme inhibitors and ␤-adrenergic blockers, when appropriate.
All patients with CHF and healthy controls with a history of allergic reaction to influenza vaccine, allergy to egg products, or moderate-tosevere acute febrile illness were excluded. Participants could not have immunologic disorders and could not be taking immunosuppressive drugs before or during the study.
The University of Wisconsin institutional review board approved the study protocol. All participants provided written informed consent in accordance with established guidelines for the protection of human subjects. 2006 . Blood samples were taken from the participants before and 2-4 weeks after vaccination to measure antibody titers, which were measured with a hemagglutination inhibition assay, then 3-4 months after vaccination to provide lymphocytes to assess T-cell responses, measured by using the trans vivo delayed-type hypersensitivity method. The timing of these samples ensured an adequate immune response. [14] [15] [16] [17] Measurements of antibody responses to influenza vaccine are similar at 2 and 4 weeks after immunization. 18 Hemagglutination Inhibition Assay Hemagglutination inhibition assay was used to measure influenza antibody concentrations after immunization. A protective antibody response to influenza vaccine equates to an antibody titer of 1:40 or greater. Seroconversion after influenza immunization was defined as a 4-fold increase in antibody concentrations. 19, 20 The assay was performed in duplicate by using standard microtiter techniques. In brief, antibodies present in the human serum inhibited influenza virus-induced agglutination of red blood cells from guinea pigs. Serial dilutions of the human sera were made. Titrated influenza antigen was incubated with the serum dilutions for 30 minutes. We added guinea pig red blood cells (50 µl of 0.5% in phosphate-buffered saline) and incubated them for 45 minutes. The influenza antibody titer was identified as the dilution of serum that no longer inhibited hemagglutination. 15, 16, 21 Trans Vivo Delayed-Type Hypersensitivity Assay
From the blood samples taken 3-4 months after vaccination, peripheral blood mononuclear cells were isolated and washed. Cells were counted and resuspended in phosphate-buffered saline. Six million cells were mixed with antigen or control. After anesthesia was induced with isoflurane, a final volume of 35 µl was injected into the footpads of SCID mice (i.e., CB.17 SCID mice with severe combined immunodeficiency, campus breeding colony). Then, using a 0.5-ml syringe with a 28-gauge needle, we injected patients' lymphocytes alone, lymphocytes with tetanus toxoid (positive control; Sanofi Pasteur, Swiftwater, PA), or lymphocytes with influenza antigens (24 hemagglutination inhibition units from each viral strain of A/H1N1, A/H3N2, and B; Centers for Disease Control and Prevention, Atlanta, GA) into the murine footpads.
Six mice were used to measure delayed-type hypersensitivity responses for each subject. We measured T-cell responses to individual influenza antigens alone and in combination. The resulting footpad swelling was an index of human T-cell sensitization. We measured footpad thickness with a dial-thickness gauge (Mitusoyo, Aurora, IL) before and 18-22 hours after injection. Background swelling due to lymphocytes and buffer was subtracted to determine antigen-specific responses.
Statistical Analysis
To identify potential differences between patients with CHF and control subjects, we compared their baseline demographics using t tests for continuous variables and 2 tests for categoric variables.
The primary study outcome variable for statistical analysis was the difference in delayedtype hypersensitivity reactivity (measured as the influenza-specific swelling of murine footpads) after vaccination. Assuming a 25-µm difference in murine footpad swelling between the groups, we needed 15 participants in each group to achieve 80% power at the 0.05 significance level. We applied a Wilcoxon rank sum test to compare differences in footpad swelling elicited by influenza antigens (three strains combined and each individually) between healthy and CHF groups. Finally, we compared the seroprotection (hemagglutination inhibition assay titer ≥ 40) and seroconversion (≥ 4-fold increase) rates in each group using 2 or Fisher exact tests. Data were analyzed based on the intent-to-treat principle.
General linear regression was used to examine associations between age, previous vaccination, and seroconversion, as well as T-cell responses to individual antigens alone and combined between the CHF and control groups. In addition, we performed subgroup analyses of the patients with CHF, examining associations between age and Tcell-mediated immune responses, as well as left ventricular ejection fraction (LVEF) and the immune responses. We constructed separate linear regression models for each variable.
Results
Participants
Eighteen patients with CHF (seven women, nine men) and 16 healthy controls (four women, 14 men) were enrolled. Mean ± SD age was similar between the groups: 54 ± 14 yrs (median age 54 yrs, range 26-81 yrs) in the CHF group and 47 ± 9 yrs (median 49 yrs, range 29-65 yrs) in the control group (p=0.11). Among the patients with CHF, mean ± SD LVEF was 40 ± 9% (median 35%, range 25-55%); 13 patients were NYHA functional class I, four were class II, and one was class III. Other baseline characteristics are shown in Table 1 .
No adverse reactions were reported after influenza vaccination.
Antibody-Mediated Responses to Influenza Vaccine
All participants demonstrated seroprotection to the influenza vaccine (Table 2) . We noted a trend toward lower seroconversion rates among patients with CHF (9 [53%] of 17 patients) compared with healthy control subjects (14 [88%] of 16 controls). The difference was short of statistical significance (p=0.057, Fisher exact test).
T-Cell Responses to Influenza Vaccine
T-cell immune response data are summarized in Table 2 . The mean time from immunization to blood sampling for delayed-type hypersensitivity did not differ significantly between patients with CHF and healthy control subjects (112 and 107 days, respectively). We observed no significant differences in responses to tetanus toxoid (positive control) between individuals with CHF and control subjects (median 68.8 and 62.5 µm, respectively, p=0.48). Median T-cell-mediated immune response to A/H3N2 was less vigorous in the CHF group than in the control group (62.5 vs 87.5 µm, unadjusted p=0.031, age-adjusted p=0.006), as shown in Table 2 . Median responses to A/H1N1 were not significantly different between the groups (56.3 vs 75 µm, p=0.11). Finally, median responses to B type were not statistically different between groups (62.5 vs 75 µm, p=0.47). We also noted no significant differences between the groups in their responses to the combination of all three vaccine viral strains (75 vs 87.5 µm, p=0.22). In the CHF group, responses to A/H3N2 were associated with age (correlation coefficient 0.51, p=0.02) but not with LVEF. Differences in influenza vaccine responses between the groups were not associated with the participants' vaccination history.
Discussion
In our study of patients with CHF and healthy individuals, we compared T-cell responses to influenza vaccination, using the trans vivo delayed-type hypersensitivity assay. This assay uses the murine footpad as the site of Tcell-mediated immune reaction. 22 Peripheral blood mononuclear cells and specific antigens are injected into the footpads of naïve, immunodeficient mice. The swelling that occurs within 24 hours of injection serves as an index of human T-cell sensitization. No swelling occurs, or no histopathologic alterations appear, in response to human peripheral blood mononuclear cells or antigen alone. Therefore, the swelling that does occur indicates T-cell-mediated activity. Trans vivo delayed-type hypersensitivity is antigen specific; that is, footpad swelling occurs only when the subject was previously exposed to the antigen. 17, 22, 23 The assay mimics physiologic conditions for immune responses and potentially reduces variability compared with in vitro methods of measuring T-cell responses.
Participants with CHF exhibited lower Tcell-mediated responses to the A/H3N2 viral strain. The composition of the trivalent vaccine changes with each influenza season. The A/H3N2 strain was the newest to be incorporated into the vaccine for the 2006-2007 season. The most widely accepted measures that indicate an appropriate immune response are based on antibody titers to one of the three viral strains in the vaccine. Seroprotection is defined as an antibody titer of 40 or higher, and seroconversion entails a 4-fold increase in the antibody titer. However, T-cell immune responses to influenza vaccine wane with increasing age and with chronic health conditions. Previous investigators found that prevaccination and postvaccination antibody titers alone did not distinguish patients with CHF who subsequently developed influenza illness and those who did not. 11 Despite antibody titers that indicated seroprotection, patients with CHF who subsequently developed laboratorydiagnosed influenza had differing T-cell responses compared with those of participants who did not develop laboratory-diagnosed influenza. In particular, individuals with laboratory-diagnosed influenza exhibited a lower interferon ␥:interleukin-10 ratio. 11 Likewise, we previously detected lower interferon ␥:interleukin-10 ratios in patients with CHF compared with healthy individuals. 13 This finding may be an indicator of high risk for influenza infection despite immunization. Similar to these findings, we found decreased T-cell immune responses, as evidenced by decreased delayed-type hypersensitivity activity to the A/H3N2 vaccine strain in patients with CHF versus healthy control subjects. These results suggested that for patients with CHF, and potentially for those with other chronic diseases, it may be advantageous to measure T-cell immune responses in addition to antibody titers. Of note, we did not detect significant differences in T-cell immune responses to the A/H1N1 and B type strains, which suggested that patients with CHF were able to mount an appropriate response to previously presented vaccine antigens but not to new vaccine antigens, as opposed to the control subjects. The fact that responses to the positive-control tetanus toxoid did not differ significantly between groups also suggested that disparities in immune responses in patients with CHF varied on the basis of previous antigen exposure.
Our previous work showed that antigenspecific antibody responses differed between patients with CHF and healthy individuals. 13 Antibody responses to the A/H3N2 antigen were reduced in patients with CHF; although, their rates of seroconversion and seroprotection were similar to those of healthy control subjects. Therefore, examining individual antigen-specific responses may yield relevant information about vaccine responses beyond seroconversion and seroprotection rates. Our results suggested that patients with CHF may rely on immunologic memory to mount appropriate antibody-mediated immune responses to an antigen. By contrast, healthy individuals are able to mount a vigorous immune response on exposure to a new antigen.
In our study, the patients with CHF were only mildly symptomatic. They had a mean LVEF of 40%, and they were optimally treated with target doses of both angiotensin-converting enzyme inhibitors and ␤-blockers. Our study data suggested that even stable, well-treated patients with CHF may be inadequately protected against influenza infection despite annual vaccination. Studies examining the benefits of influenza immunization in patients with cardiovascular disease are favorable; however, future studies should explore additional or alternate influenza vaccination strategies for patients with CHF.
Several limitations of our study must be considered. First, immune responses to influenza vaccination decrease with age, and our healthy control group trended to be younger than our CHF group. Declining antibody responses to influenza vaccine have been observed in the elderly. 24, 25 However, both groups in our study had mean and median ages well below 65 years. Moreover, we statistically adjusted for age, and the association between CHF with reduced T-cell responses to A/H3N2 remained significant. In addition, our study participants had mildly symptomatic, stable CHF. The generalizability of our results to a wide group of patients, especially those with advanced CHF, is unknown.
Second, we did not find statistically significant differences in seroconversion between groups. However, our study was designed to detect differences in T-cell responses; therefore, it is possible that our analysis was not powered to capture differences in seroconversion rates. Because of our small sample sizes, antibodymediated immune responses might have significantly differed between the study groups for the A/H1N1 and B type viral strains in the vaccine. As such, antigen-specific differences in immune responses should be explored closely in a larger cohort.
Finally, we were unable to correlate differences in immune responses to subsequent rates of influenza infection between the study groups. A much larger sample size is necessary to detect differences in influenza infection rates between populations, particularly immunized populations. Future work should specifically address the issue of individual-strain, vaccine-induced T-cell responses and clinical correlations with influenza infection rates.
Conclusion
Patients with CHF had decreased T-cell immune responses to the A/H3N2 influenza strain compared with healthy control subjects despite similar rates of seroprotection and seroconversion. Differences in T-cell immune responses to the A/H1N1 and B type strains were not found to be significant between the two groups, however, which suggests that patients with CHF can mount an appropriate response to vaccine antigens previously presented but less so to new antigens. This finding is supported by the fact that responses to the positive-control tetanus toxoid also did not differ significantly between the groups. These findings suggest that patients with CHF may be at increased risk for influenza infection, and clinicians may want to investigate other or additional strategies for influenza vaccination.
